-
Innovative features inspired by clinician feedback make delivering
therapy simpler and more efficient
-
Incorporates the latest technology to increase accuracy and
performance in delivering therapy for critically ill patients in the
intensive care unit (ICU)
-
New TherMax Blood Warmer also receives CE mark to deliver
effective blood warming for a variety of organ support therapies
DEERFIELD, Ill.--(BUSINESS WIRE)--
Baxter International Inc. (NYSE:BAX), a global leader in acute care,
announced today the company received CE mark of both its PrisMax
system and its TherMax blood warmer. PrisMax is the
company’s next-generation technology for continuous renal replacement
and organ support therapies. Designed with input from more than 650
healthcare practitioners around the world, the PrisMax system
features innovative technology to make delivering therapy simpler and
more efficient while also improving treatment accuracy in the ICU.
Baxter kicked off the launch of the PrisMax system at the 2018
European Society of Intensive Care Medicine (ESICM) congress in Paris
last week.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20181029005222/en/
Baxter Receives CE Mark for PrisMax, the Next-Generation System for Continuous Renal Replacement and Organ Support Therapies (Photo: Business Wire)
“Baxter has been a leader in continuous renal replacement therapy (CRRT)
technology for more than 20 years. We’ve built on this expertise to
bring to market the most advanced technology currently available that
directly addresses what clinicians have said they need to better treat
patients: simplicity, efficiency and accuracy,” said Reaz Rasul, general
manager of Baxter’s Acute Therapies business. “The PrisMax system
is foundational to accomplishing our shared vision to help transform
care for critically ill patients and establish best-in-class treatments
for a variety of organ support therapies.”
Building on Baxter’s leading Prismaflex technology currently used
by hospitals in more than 90 countries, the PrisMax system, in
combination with specialty dialyzers, delivers a complete range of
extracorporeal (outside the body) therapies to remove waste products,
excess fluids and inflammatory mediators, to help manage patients with
acute kidney injury (AKI), and as an aid in sepsis management. AKI is an
increasingly common complication of acute illnesses in intensive care
units and hospitals.123
“Our assessment of the PrisMax system across seven ICUs in six
countries concluded that the device features several important
enhancements that contribute to safety, efficiency and user
friendliness. The launch of PrisMax is a big step forward for
clinicians’ abilities to treat patients in the ICU more effectively,”
said Marcus Broman, M.D., Department of Perioperative and Intensive Care
of Skåne University Hospital in Lund, Sweden, and lead author of a
publication about the results.4
The prospective, multicenter, international pilot study found that PrisMax
delivered significant improvements in areas that impact efficiency and
ease of use, including the time needed for bag changes, the number of
informational and malfunction alarms, how often the blood pump stops,
filter life and machine downtime. 4 The findings were
published earlier this year in Blood Purification. 4
The TherMax blood warmer, which is used alongside the PrisMax
system, is a critical component for extracorporeal therapies as a
patient’s blood is purified outside of the body and must be at a certain
temperature prior to returning to the body. TherMax uses a
bi-directional connection with the PrisMax system to help meet
warming targets by automatically adjusting heating to meet the
prescribed return blood temperature. 5 The TherMax
blood warmer also includes several advanced patient safety features to
help control blood return temperature, detect leaks, and to ensure the
correct setup.5
Baxter intends to commercially launch PrisMax and TherMax
in more than 19 countries across Europe, with hospitals in Denmark,
France, Italy and Sweden to be among the first to receive the new
devices.
About Our Acute Therapies Portfolio
A leader in multi-organ support therapy options, Baxter has been at the
forefront of advancing new technologies and revolutionizing treatment
for critically ill patients around the world. Baxter’s leading Prismaflex
system has offered clinicians the flexibility to meet patients’ diverse
needs and powered our portfolio of products to deliver a complete range
of extracorporeal (outside the body) blood purification therapies to
help manage patients with acute kidney injury (AKI),and with our
specialty dialyzers aid in the management of sepsis. PrisMax,
Baxter’s next generation system, builds on our legacy of proven
performance with enhancements designed to improve accuracy and system
performance while making it simpler and more efficient for clinicians to
deliver therapy.
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading
portfolio of critical care, nutrition, renal, hospital and surgical
products. For more than 85 years, we’ve been operating at the critical
intersection where innovations that save and sustain lives meet the
healthcare providers that make it happen. With products, technologies
and therapies available in more than 100 countries, Baxter’s employees
worldwide are now building upon the company’s rich heritage of medical
breakthroughs to advance the next generation of transformative
healthcare innovations. To learn more, visit www.baxter.com and
follow us on Twitter, LinkedIn and Facebook.
Rx Only.For safe and proper use of this device, refer to
the full Instructions for Use.
This release includes forward-looking statements concerning PrisMax
and TherMax, including potential benefits associated with their
use and information about planned commercial launches. The statements
are based on assumptions about many important factors, including the
following, which could cause actual results to differ materially from
those in the forward-looking statements: satisfaction of regulatory and
other requirements; actions of regulatory bodies and other governmental
authorities; product quality, manufacturing or supply, or patient safety
issues; changes in law and regulations; and other risks identified in
Baxter's most recent filing on Form 10-K and other SEC filings, all of
which are available on Baxter's website. Baxter does not undertake to
update its forward-looking statements.
Baxter, PrisMax, TherMax and Prismaflex are
registered trademarks of Baxter International Inc.
1 Siew ED, Davenport A: The growth of acute kidney injury: a
rising tide or just closer attention to detail? Kidney Int 2015;87:46-61.
2
O'Connor ME, Kirwan CJ, Pearse RM, Prowle JR: Incidence and associations
of acute kidney injury after major abdominal surgery. Intensive Care Med
2016;42:521-530.
3 Susantitaphong P, Cruz DN, Cerda J,
Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL: World incidence of
AKI: a meta-analysis. Clin J Am Soc Nephrol 2013;8:1482-1493.
4
Broman M, et al. Blood Purif. 2018;46:220-227.
5
Baxter - TherMax Operators Manual. AW7006 Rev A 2018;Sep.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181029005222/en/
Baxter International Inc.
Media Contact
Beth Mueller,
(224) 948-5353
media@baxter.com
or
Investor
Contact
Clare Trachtman, (224) 948-3085
Source: Baxter International Inc.